Table 2.
Summary of response rates before and after PSM.
| All response, n (%) | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| DEB-TACE+ICIs (n=20) | Chemotherapy (n=29) | P | DEB-TACE+ICIs (n=20) | Chemotherapy (n=20) | P | ||
| CR | 1(5.0) | 0 (0) | 0.224 | 1 (5.0) | 0 (0) | 0.311 | |
| PR | 10 (50.0) | 4 (13.8) | 0.006 | 10 (50.0) | 4 (20.0) | 0.047 | |
| SD | 7 (35.0) | 20 (69.0) | 0.019 | 7 (35.0) | 13 (65.0) | 0.058 | |
| PD | 2 (10.0) | 5 (17.2) | 0.476 | 2 (10.0) | 3 (15.0) | 0.633 | |
| ORR DCR |
11 (55.0) 18 (90.0) |
4 (13.8) 24 (82.8) |
0.002 0.476 |
11 (55.0) 18 (90.0) |
4 (20.0) 17 (85.0) |
0.022 0.633 |
|
PSM, propensity score matching; DEB-TACE+ICIs, drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.